Elan Pharmaceuticals
E133121
analgesic drug
biotechnology company
drug delivery business unit
monoclonal antibody
monoclonal antibody drug
pharmaceutical company
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Elan Drug Technologies | 1 |
| Elan Pharmaceuticals canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1172127 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Elan Pharmaceuticals Context triple: [Tysabri, developedBy, Elan Pharmaceuticals]
-
A.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
-
B.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
C.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
D.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
E.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Elan Pharmaceuticals Target entity description: Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
A.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
-
B.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
C.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
D.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
E.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
analgesic drug
ⓘ
biotechnology company ⓘ drug delivery business unit ⓘ monoclonal antibody ⓘ monoclonal antibody drug ⓘ pharmaceutical company ⓘ pharmaceutical company ⓘ |
| acquiredBy | Perrigo ⓘ |
| acquisitionCompletedIn | 2013 ⓘ |
| coDevelopedWith |
Biogen
ⓘ
surface form:
Biogen Idec
|
| collaboratedWith |
Johnson & Johnson
ⓘ
Wyeth ⓘ |
| country | Ireland ⓘ |
| defunctSince | 2013 ⓘ |
| developed |
Tysabri
ⓘ
bapineuzumab ⓘ |
| developedFor | Alzheimer's disease ⓘ |
| experienced | Tysabri market withdrawal in 2005 ⓘ |
| focusesOn |
autoimmune diseases
ⓘ
neurological diseases ⓘ |
| foundedIn | 1969 ⓘ |
| founder | Donal E. R. Geaney ⓘ |
| hadControversy | Tysabri safety concerns ⓘ |
| hadEmployeeCountApprox | 1700 ⓘ |
| hadProduct | Prialt ⓘ |
| hadSubsidiary |
Elan Pharmaceuticals
self-linksurface differs
ⓘ
surface form:
Elan Drug Technologies
|
| headquartersLocation | Dublin ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| knownFor | drug delivery technologies ⓘ |
| laterResumed | Tysabri marketing ⓘ |
| listedOn | Irish Stock Exchange ⓘ |
| operatedIn |
Europe
ⓘ
Ireland ⓘ United States of America ⓘ
surface form:
United States
|
| researchArea |
Alzheimer's disease
ⓘ
Parkinson's disease ⓘ autoimmune disorders ⓘ multiple sclerosis ⓘ |
| specializesIn |
central nervous system disorders
ⓘ
neurodegenerative diseases ⓘ |
| status | defunct ⓘ |
| stockExchange | New York Stock Exchange ⓘ |
| tickerSymbol | ELN ⓘ |
| tradedAs | NYSE:ELN ⓘ |
| treats |
Crohn's disease
ⓘ
multiple sclerosis ⓘ |
| usedFor | severe chronic pain ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Elan Pharmaceuticals Description of subject: Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Elan Drug Technologies